NKMax
Scope
Date
~
-
Bio & PharmaNKMax to perform first tests on dementia cell therapy in US
NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...
Oct 26, 2023 (Gmt+09:00)
-
Bio & PharmaNKMax's US subsidiary listed on Nasdaq
South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...
Oct 05, 2023 (Gmt+09:00)
-
Bio & PharmaNKMax to supply health functional food to Chinese company
South Korean natural killer cell drug maker NKMax Co. announced in a regulatory filing on Friday that it has signed a supply contract with China's S...
Jul 21, 2023 (Gmt+09:00)
-
Bio & PharmaNKMax submits US subsidiary's securities report to SEC
The listing in the US of NKGen Biotech, the American subsidiary of South Korean developer of natural killer (NK) cell therapy NKMax Co., is coming i...
May 17, 2023 (Gmt+09:00)
-
Bio & PharmaS.Korean biotech NKMax’s unit aims for US IPO
NKMax Co., a South Korean cancer drug maker, is in talks with local and foreign investors in a bid to list its California-based unit NKGen Biotech I...
Mar 14, 2023 (Gmt+09:00)
Latest News
- 1 Korea’s top cinema chains seek merger to counter box office slump
- 2 S.Korea’s GEPS to commit $143 million to foreign mid-cap buyout funds
- 3 CJ CheilJedang to open $72 mn dumpling plant in Japan
- 4 LG Electronics breaks ground on $600 million home appliance plant in India
- 5 KakaoBank posts record Q1 profit, eyes Thai expansion after Indonesia
